The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Marixino (previously Maruxa) memantine Generic | KRKA tovarna zdravil d.d. Novo mesto | Alzheimer Disease | 🇪🇺 EU 2013-04-28 | Order → |
| Nemdatine memantine Generic | Actavis Group PTC ehf | Alzheimer Disease | 🇪🇺 EU 2013-04-22 | Order → |
| Memantine LEK memantine Generic | Pharmathen S.A. | Alzheimer Disease | 🇪🇺 EU 2013-04-21 | Order → |
| Memantine Mylan memantine Generic | Mylan Pharmaceuticals Limited | Alzheimer Disease | 🇪🇺 EU 2013-04-21 | Order → |
| Hexacima diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed) | Sanofi Winthrop Industrie | Hepatitis B; Tetanus; Immunization; Meningitis, Haemophilus; Whooping Cough; Poliomyelitis; Diphtheria | 🇪🇺 EU 2013-04-17 | Order → |
| Hexyon diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed) | Sanofi Winthrop Industrie | Hepatitis B; Tetanus; Immunization; Meningitis, Haemophilus; Whooping Cough; Poliomyelitis; Diphtheria | 🇪🇺 EU 2013-04-17 | Order → |
| Imatinib Actavis imatinib Generic | Actavis Group PTC ehf | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Myelodysplastic-Myeloproliferative Diseases; Hypereosinophilic | 🇪🇺 EU 2013-04-17 | Order → |
| Bosulif bosutinib | Pfizer Europe MA EEIG | Leukemia, Myeloid | 🇪🇺 EU 2013-03-27 | Order → |
| Actelsar HCT telmisartan;hydrochlorothiazide Generic | Actavis Group PTC ehf | Essential Hypertension | 🇪🇺 EU 2013-03-13 | Order → |
| Jetrea ocriplasmin | Inceptua AB | Retinal Diseases | 🇪🇺 EU 2013-03-13 | Order → |
| Tolucombi telmisartan;hydrochlorothiazide Generic | KRKA tovarna zdravil d.d. Novo mesto | Hypertension | 🇪🇺 EU 2013-03-13 | Order → |
| Perjeta pertuzumab | Roche Registration GmbH | Breast Neoplasms | 🇪🇺 EU 2013-03-04 | Order → |
| Selincro nalmefene | H. Lundbeck A/S | Alcohol-Related Disorders | 🇪🇺 EU 2013-02-24 | Order → |
| Adasuve loxapine | Ferrer Internacional S.A. | Schizophrenia; Bipolar Disorder | 🇪🇺 EU 2013-02-20 | Order → |
| Zaltrap aflibercept | Sanofi Winthrop Industrie | Colorectal Neoplasms | 🇪🇺 EU 2013-02-01 | Order → |
| Lyxumia lixisenatide | Sanofi Winthrop Industrie | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2013-01-31 | Order → |
| BindRen colestilan | Mitsubishi Pharma Europe Ltd | Hyperphosphatemia | 🇪🇺 EU 2013-01-21 | Order → |
| Ryzodeg insulin degludec;insulin aspart | Novo Nordisk A/S | Diabetes Mellitus | 🇪🇺 EU 2013-01-21 | Order → |
| Tresiba insulin degludec | Novo Nordisk A/S | Diabetes Mellitus | 🇪🇺 EU 2013-01-20 | Order → |
| Amyvid florbetapir (18F) | Eli Lilly Nederland B.V. | Radionuclide Imaging | 🇪🇺 EU 2013-01-14 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.